196P Final analysis of PUFFIN: A phase III, randomised double-blind, placebo (Pla)-controlled study of pertuzumab, trastuzumab and docetaxel (PHD) for Chinese patients (pts) with previously untreated HER2-positive locally recurrent or metastatic breast cancer (LR/MBC)

• DOI: 10.1016/j.annonc.2022.03.215
• Publication Date: 2022-05-05T13:17:30Z
• Authors: B. Xu; W. Li; Q. Zhang; Q. Li; X. Wang; H. Li; T. Sun; Y. Yin; H. Zheng; J. Feng; H. Zhu; A. Siddiqui; H.N. Macharia; A. Knott
• Keywords: 03 medical and health sciences; 0302 clinical medicine